Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CONKO-006 additive therapy in the R1 resected pancreatic cancer with Gemcitabine plus sorafenib versus Gemcitabine plus placebo over 12 months - one double-blind, placebo-controlled Phase IIb study.

Next Previous
Trial Profile

CONKO-006 additive therapy in the R1 resected pancreatic cancer with Gemcitabine plus sorafenib versus Gemcitabine plus placebo over 12 months - one double-blind, placebo-controlled Phase IIb study.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Therapeutic Use

Most Recent Events

  • 29 Apr 2021 Results of pooled analysis from three clinical studies: CONKO-001, CONKO-005, and CONKO-006 published in the European Journal of Cancer
  • 08 Sep 2017 Status changed from active, no longer recruiting to completed.
  • 11 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by German Clinical Trials Register record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top